#ESHAL2022 - ONLY TWO WEEKS LEFT TO SUBMIT YOUR ABSTRACT OR CLINICAL CASE

ESH 3rd How to Diagnose and Treat

ACUTE LEUKAEMIAS

March 11-13, 2022

Budapest, Hungary

#ESHAL2022

---

THERE ARE ONLY TWO WEEKS LEFT:
SUBMIT YOUR ABSTRACT OR CLINICAL CASE NOW!
DEADLINE: JANUARY 9th, 2022
DO NOT MISS THE OPPORTUNITY!

Abstracts and clinical cases are eligible to be selected
for an oral or a poster presentation.

---

REGISTRATION IS OPEN!

Join us in Budapest!

---

About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. An important incentive will be to promote interaction between the speakers and participants.

Novel and still evolving insights into the biology and diagnosis of acute leukaemias, including acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease.

The programme of this “3rd How to Diagnose and Treat: Acute Leukaemias” meeting will integrate of genomic analysis and cutting-edge technics in routine diagnosis, gene mutation-directed therapies and new standard treatment algorithms, allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.

For more information, click here!

---

CONFERENCE MAIN TOPICS:

• Diagnosis and rare diseases
• Measurable Residual Disease (MRD)
• Leukaemia treatment dilemmas
• Intensive chemotherapy for older fit patients
• MRD level before transplant
• Leukaemia treatment challenges
• Ph-positive ALL
• CAR-T cell for ALL patients
• Immune therapies to treat leukaemia patients
• Haematopoietic stem cell transplantation

---

LEARNING OBJECTIVES:

Upon completion of this CME activity, participants should be able to:

• Get knowledge of diagnostic tests needed to optimally manage patients with AML and ALL
• Get insight in new treatment strategies available for AML and ALL patients for front-line and for salvage therapy
• Maintenance treatment
• Understand the value of measurable residual disease (MRD) levels to direct acute leukaemia therapy
• Gain insight into emerging mechanisms associated with clinical resistance and leukaemia escape
• Understand the effects and place of new immunotherapies with respect to standard or new HSCT procedures

---

The programme will include:

Plenary Sessions - Interactive Case Presentations - Roundtables
Panel Discussions - Debates - Meet the Expert Sessions
Poster Walks - Voting technology

---